Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets 2012th Edition

From the reviews:

“The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice. … certainly appeal to a wide range of readers interested in the research aspect of RCC, such as graduate and medical students, postdoctoral fellows, as well as basic scientists and clinicians interested in the basic and translational research in RCC.” (Jose A. Karam and Christopher G. Wood, Urology, Vol. 81 (1), January, 2013)

“Editors Figlin, Rathmell and Rini, with the help of 20 contributors compiled recent advances in biology and related therapeutic aspects. … We recommend this excellent textbook to practitioners and researchers involved in kidney cancer. The high quality level of the text and the outstanding illustrations makes this book an essential purchase.” (European Urology Today, June-July, 2012)

“This book by Figlin et al. is … timely, and serves to bring the reader up-todate with what has been a tremendously exciting time in the field. … We found it comprehensive, well written and well illustrated. … Overall, we found this to be an excellent book that we highly recommend. … It would be equally well placed on the shelf of physicians and researchers … and those with an interest in the field would do well to have read it.” (Naveen S. Vasudev and James M. G. Larkin, British Journal of Clinical Pharmacology, Summer, 2012)

This volume examines every major topic area in the modern era of renal carcinoma biology and treatment. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease. These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy.

Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways. This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations.